Capsida Biotherapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 59

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $70M

  • Investors
  • 5

Capsida Biotherapeutics General Information

Description

Developer of targeted gene therapies designed to treat debilitating and life-threatening genetic disorders in both the central nervous system and non-CNS indications. The company's therapies use an adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the diseased organ while limiting the transduction of tissues and cells not relevant to the target disease, enabling healthcare providers to have access to targeted therapies to improve patient health outcomes.

Contact Information

Website
www.capsida.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1300 Rancho Conejo Boulevard
  • Newbury Park
  • Thousand Oaks, CA 91320
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1300 Rancho Conejo Boulevard
  • Newbury Park
  • Thousand Oaks, CA 91320
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Capsida Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 23-Feb-2023 $70M Completed Generating Revenue
2. Early Stage VC (Series A) 28-Apr-2021 Completed Generating Revenue
1. Corporate 28-Apr-2021 $90M $90M Completed Generating Revenue
To view Capsida Biotherapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Capsida Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of targeted gene therapies designed to treat debilitating and life-threatening genetic disorders in both the c
Drug Discovery
Thousand Oaks, CA
59 As of 2026

Barcelona, Spain
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Capsida Biotherapeutics Competitors (43)

One of Capsida Biotherapeutics’s 43 competitors is Minoryx, a Venture Capital-Backed company based in Barcelona, Spain.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Minoryx Venture Capital-Backed Barcelona, Spain
Vedanta Biosciences Venture Capital-Backed Cambridge, MA
Priothera Venture Capital-Backed Dublin, Ireland
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Sernova Biotherapeutics Corporation Mississauga, Canada
You’re viewing 5 of 43 competitors. Get the full list »

Capsida Biotherapeutics Patents

Capsida Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026136871-A1 Adeno-associated virus compositions having increased brain enrichment Pending 20-Dec-2024
WO-2026096911-A1 Gene therapy for friedreich's ataxia Pending 01-Nov-2024
WO-2026050233-A1 Novel adeno-associated virus compositions having increased brain enrichment Pending 26-Aug-2024
WO-2025231383-A1 Compositions and methods of delivering a therapeutic across the blood-brain barrier via the pl16 receptor Pending 03-May-2024
WO-2025213066-A1 Adeno-associated virus compositions for treating parkinson's disease (pd) Pending 05-Apr-2024 A61P25/00
To view Capsida Biotherapeutics’s complete patent history, request access »

Capsida Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Capsida Biotherapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
AbbVie Corporation Minority
Versant Ventures Venture Capital Minority
Westlake Village BioPartners Venture Capital Minority
Lilly USA Corporation
To view Capsida Biotherapeutics’s complete investors history, request access »

Capsida Biotherapeutics FAQs

  • When was Capsida Biotherapeutics founded?

    Capsida Biotherapeutics was founded in 2019.

  • Where is Capsida Biotherapeutics headquartered?

    Capsida Biotherapeutics is headquartered in Thousand Oaks, CA.

  • What is the size of Capsida Biotherapeutics?

    Capsida Biotherapeutics has 59 total employees.

  • What industry is Capsida Biotherapeutics in?

    Capsida Biotherapeutics’s primary industry is Drug Discovery.

  • Is Capsida Biotherapeutics a private or public company?

    Capsida Biotherapeutics is a Private company.

  • What is Capsida Biotherapeutics’s current revenue?

    The current revenue for Capsida Biotherapeutics is .

  • How much funding has Capsida Biotherapeutics raised over time?

    Capsida Biotherapeutics has raised $300M.

  • Who are Capsida Biotherapeutics’s investors?

    AbbVie Ventures, AbbVie, Versant Ventures, Westlake Village BioPartners, and Lilly USA have invested in Capsida Biotherapeutics.

  • Who are Capsida Biotherapeutics’s competitors?

    Minoryx, Vedanta Biosciences, Priothera, Sangamo Therapeutics, and Sernova Biotherapeutics are some of the 43 competitors of Capsida Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process